Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402911 | 0.89 | MAOB (0.57) | MAOBLMNAPDE3BPDE3AP2RY12 | |
| SCHEMBL13954885 | 0.86 | MAOB (0.67) | MAOBLMNAPDE3BPDE3AP2RY12 | |
| SCHEMBL13954886 | 0.83 | MAOB (0.64) | MAOBLMNAPDE3BPDE3AP2RY12 | |
| SCHEMBL13954884 | 0.82 | MAOB (0.62) | MAOBLMNAPDE3BPDE3AP2RY12 | |
| SCHEMBL891410 | 0.81 | MAOB (0.51) | MAOBPDE3BPDE3AP2RY12PGR | |
| SCHEMBL13015478 | 0.79 | MAOB (0.58) | MAOBLMNAPDE3BPDE3APGR | |
| SCHEMBL30627401 | 0.79 | MAOB (0.58) | MAOBLMNAPDE3BPDE3APGR | |
| SCHEMBL8162661 | 0.78 | MAOB (0.74) | MAOBLMNAPDE3BPDE3AP2RY12 | |
| SCHEMBL19586360 | 0.78 | MAOB (0.77) | MAOBLMNA | |
| SCHEMBL31601553 | 0.77 | MAOB (0.56) | MAOBPDE3BPDE3AP2RY12PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |